• Markets
    • icon
  • Companies
OSL · ASX

OncoSil Medical Limited (ASX:OSL)

AU$0.009

 0.0 (0.0%)
ASX:Live
01/12/2023 01:42:23 PM
HALO Ords GROWTH AUS Big Candle All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

OSL Overview

OSL Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About OSL

Website

OncoSil Medical Limited

Telephone

61.2.8935.9629

Address

Level 5 7 Eden Park Drive Macquarie Park, New South Wales (NSW) 2113

Description

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.

OSL Price Chart

Key Stats

Market Cap

AU$17.78M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.04

Trade Value (12mth)

AU$7,458.00

1 week

12.5%

1 month

0%

YTD

-75.92%

1 year

-76.92%

All time high

0.216424

Key Fundamentals

EPS 3 yr Growth

92.300%

EBITDA Margin

%

Operating Cashflow

-$11m

Free Cash Flow Return

-106.70%

ROIC

-107.00%

Interest Coverage

-1,135.60

Quick Ratio

7.20

Other Data

Shares on Issue (Fully Dilluted)

1310m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

OSL Announcements

Latest Announcements

Date Announcements

31 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

31 October 22

Change of Registry Address

×

Change of Registry Address

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Two key treatment centres treat first patients with OncoSil

×

Two key treatment centres treat first patients with OncoSil

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

31 August 23

Corporate Governance Statement

×

Corporate Governance Statement

31 August 23

Appendix 4G

×

Appendix 4G

31 August 23

Otto Buttula retires and Douglas Cubbin appointed Chair

×

Otto Buttula retires and Douglas Cubbin appointed Chair

31 August 23

Final Director's Interest Notice OB

×

Final Director's Interest Notice OB

31 August 22

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

31 August 22

Appendix 4E Announcement

×

Appendix 4E Announcement

31 August 22

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

31 August 11

NeuroDiscovery Ltd - Annual Report and Appendix 4E (NDL-AU)

×

NeuroDiscovery Ltd - Annual Report and Appendix 4E (NDL-AU)

31 August 10

Annual Report and Appendix 4E (NDL-AU)

×

Annual Report and Appendix 4E (NDL-AU)

30 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 October 18

2018 AGM CEO Presentation

×

2018 AGM CEO Presentation

30 October 18

Results of Annual General Meeting 2018

×

Results of Annual General Meeting 2018

30 October 18

Results of Annual General Meeting 2018 - Amended

×

Results of Annual General Meeting 2018 - Amended

30 June 23

Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer

×

Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer

30 June 22

FY 2023 Strategic Update

×

FY 2023 Strategic Update

30 August 13

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

29 October 19

OncoSil AGM CEO Presentation

×

OncoSil AGM CEO Presentation

29 November 23

OncoSil onboards first patient in PANCOSIL Clinical Trial

×

OncoSil onboards first patient in PANCOSIL Clinical Trial

29 November 23

Presentation to Annual General Meeting

×

Presentation to Annual General Meeting

29 November 23

Results of Annual General Meeting

×

Results of Annual General Meeting

29 June 23

Notification of cessation of securities - OSL

×

Notification of cessation of securities - OSL

OSL Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -96.2 -4.9 6.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.2 21.9 32.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -20.5 -31.2 -83.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.5 -22.3 -45.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,019 998 1,130 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,019 998 1,130 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 8.8 58.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 5 5 6 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -6 -7 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4,071.3 -8.0 3.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2,922.6 -2,902.2 -1,766.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 3,023 3,002 1,866 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -11 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.1 1.4 -9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,370.2 -4,867.5 -3,366.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -61.3 1.9 -10.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,457.0 -4,922.3 -3,414.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -12 -12 -12 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -11 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -144.8 -2.8 -5.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4,896.8 -4,627.8 -3,085.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -10 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 9 9 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -98.1 -14.1 -12.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -41.6 -43.6 -30.9 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 11 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 14 13 11 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -11 -9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 12 11 10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 12 11 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -45.1 -6.0 -12.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -73.7 -82.1 -98.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -89.2 -96.1 -114.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -68.0 -96.5 -116.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -61.5 -92.0 -107.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -52.0 -86.7 -106.7 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -726.6 -574.9 -1,135.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.0 1.0 0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -100.5 -98.3 -93.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.4 7.2 7.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.4 7.2 7.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 89.9 88.5 83.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -413.3 -571.9 -721.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.1 0.2 0.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 575.8 401.7 261.1 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -5,402.3 -4,986.6 -3,384.1 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -81.3 -88.4 -108.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -73.7 -82.1 -98.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -89.2 -96.1 -114.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -89.2 -96.1 -114.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 3,415.1 1,644.9 1,088.7 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 3,415.1 1,644.9 1,088.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 73.2 56.6 50.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 3,342.0 1,588.3 1,038.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OSL Shortsell

Frequently Asked Questions

The current share price of OncoSil Medical Limited (OSL:ASX) is AU$0.009.
The 52-week high share price for OncoSil Medical Limited (OSL:ASX) is AU$0.04.
The 52-week low share price for OncoSil Medical Limited (OSL:ASX)? is AU$0.01.
OncoSil Medical Limited (OSL:ASX) does not pay a dividend.
OncoSil Medical Limited (OSL:ASX) does not pay a dividend.
OncoSil Medical Limited (OSL:ASX) has a franking level of 0%.
OncoSil Medical Limited (OSL:ASX) is classified in the Healthcare.
The current P/E ratio for OncoSil Medical Limited (OSL:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.